Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive Q3 results
Pfizer raised its 2026 revenue forecast to $62B-$64B and earnings to $2.95-$3.05 per share, citing strong Q3 results driven by Eliquis and Padcev. CEO Bourla attributed the increase to strategic confidence. The company's acquisitions, including Seagen and Metsera, aim to offset COVID-19 product declines. Q3 revenue was $16.58B, exceeding estimates. Pfizer also appointed Cecile Guegan as CFO.
How this was made
The 30-second read
Why it matters
The guidance lift reflects successful integration of recent acquisitions and strong demand for Eliquis, suggesting continued momentum.
Market read
Pfizer's upgraded outlook is a material catalyst for the stock and may influence sector sentiment.
What to watch
Potential headwinds from upcoming patent expirations and regulatory scrutiny on drug pricing could temper upside.
Background
Pfizer's recent acquisitions of Seagen and Metsera have expanded its oncology and obesity drug portfolios, setting the stage for higher growth.
Ticker impact
Pfizer raised its full-year profit and revenue forecasts for 2026, citing strong Q3 results from Eliquis and the newly acquired cancer drug Padcev.
likely upward pressure as investors price in the higher earnings outlook
The guidance increase is material, first disclosed today, and reflects better-than-expected sales, which typically drives a positive market reaction.
Market effects
Boosts outlook for the broader pharma sector, especially companies with strong oncology pipelines.
U.S. market may see modest gains in healthcare indices.
Reinforces confidence in large-cap biotech earnings globally.
Counterpoint
If the guidance raise is already priced in, the stock could face a short‑term pullback.
Key entities
- companyPfizer
Global pharmaceutical company raising 2026 guidance.
- productEliquis
Blockbuster blood thinner contributing to sales growth.
